Johnson & Johnson announces real-world evidence and phase III data confirming strong and long-lasting protection of single-shot COVID-19 vaccine in the U.S.
Alvotech provides update on FDA action regarding AVT 02, proposed high-concentration biosimilar to Humira.
CHMP recommends Hukyndra a biosimilar to Humira for infammatory and autoimmune disorders.
CHMP recommends Qinlock to treat advanced gastrointestinal stromal tumor.
CHMP recommends Artesunate Amivas for the initial treatment of severe malaria.
CHMP negative for approval of Raylumis as a proposed treatment for pain associated with osteoarthritis.
CHMP recommends Gavreto to treat RET fusion-positive advanced non small lung cancer.
FDA grants accelerated approval to Tivdak for the treatment of metastatic cervical cancer.
Mirati Therapeutics presents positive clinical data with adagrasib as monotherapy and + cetuximab.
Skyrizi filed with FDA for moderate to severe Crohn's disease.
Phase II/III trial data for Comirnaty shows favourable safety profile in 5-11 year olds.
Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet.
FDA accepts BMS 986016 + Opdivo for priority review in metastatic melanoma.
FDA approves Biooviz, a Lucentis biosimilar.
Mirati Therapeutics announces positive phase II topline results for adagrasib.
ESMO late-breaking data show Libtayo and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC.
Genmab + Seagen present interim results from the innovaTV 205 study.
Keytruda + chemotherapy reduced risk of death by 27% versus chemotherapy as first-line treatment for patients with metastatic triple-negative breast cancer whose tumors expressed PD-L1
Novartis presents new Kisqali data from phase III MONALEESA-2 study
Keytruda demonstrated superior recurrence-free survival in patients with resected high-risk stage II melanoma.
Keytruda + chemotherapy with or without bevacizumab reduced risk of death by one-third versus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent or metastatic cervical cancer.
Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN phase III trial in extensive-stage small cell lung cancer.- AstraZeneca
BeiGene receives positive CHMP opinion for Brukinsa for the treatment of adults with Waldenström’s macroglobulinemia.
Enhertu demonstrated robust and durable tumour response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer. AstraZeneca + Daiichi Sankyo
Enhertu reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.- AstraZeneca + Daiichi Sankyo.
CHMP recommends Jyseleca to treat moderately to severely active ulcerative colitis.-Galapagos NV.
DisCoVeRy trial of Verklury concluded there was no clinical benefit in hospitalised patients with COVID 19.-Gilead Sciences
Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases
Clinical value beyond price alone: biosimilars improve patient access to treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
